Could Vascepa be underpriced?

We're about to get very busy!!

Amarin Corp., the maker of a promising heart-disease capsule derived from purified fish oil, has been one of the biggest biopharma surprises of the past decade. Last year, the company’s American depositary receipts more than tripled after a clinical trial found that the pill, Vascepa, significantly cuts the risk of heart attack and stroke.

Vascepa is already available for a subset of patients, and Amarin is waiting on approval from the Food and Drug Administration to market the drug – which costs about $300 per month before discounts – to a much larger population. In the meantime, a draft report released Wednesday by the Institute for Clinical and Economic Review (ICER), an independent group that assesses the value of medicines, revealed another way in which Vascepa is unique: it just might be underpriced relative to its potential benefit as an effective treatment for staving off America’s leading cause of death.

Post A Reply

Report this entire thread

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a thread a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the thread has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.

The Amarin Savings Program is a great deal and a lot of the StockTwits community has shown the pricing with the program, which is as little as $9 for 90 days. They say that pricing is saving patients up to $110 per month, or $330 for a 90-day prescription. That program is when using the Vascepa Savings Card.

I don't think this pricing without the savings card will last that long. Amarin is using it as a strategy to get more patients using the drug and I'm sure the list price will increase over time. It's all but certain the price increases when Amarin gets acquired.

The pricing is smart for now.

post

JT is smart and while it could be underpriced for the benefits patients receive, they are working to improve the manufacturing process so the margins are always improving. JT and team are getting ready for label expansion and the demand it will create.

post

Absurd....

Is a black box label even on the table? I mean we are talking about fish oil, ha.

post

Why in the world would there be a black box?

Absurd....

post

Could we see a black box for Vascepa??

Why in the world would there be a black box?

post

Loading...


Report this post

The reason we ask for your email address is to ensure the reporting feature is not abused. Once you report a post a confirmation email will be sent to you requiring that you did in fact mean to do this action. This also gives us a way to get in touch with you privately to discuss your reasoning if we feel the post has been reported without merit.

Your email address will never be used for any other reason and will never be sold to email marketers.

A reason is required.